Neuroprotective biologic treatment for neuropathies

This technology leverages the mesencephalic astrocyte derived neurotrophic factor (MANF) protein as a biologic solution for preventing, reducing development of, or treating various neuropathies, including Chemotherapy Induced Peripheral Neuropathy (CIPN).

Unmet Need: Effective and non-invasive therapy for neuropathies

Current treatments for CIPN often force alterations in chemotherapy regimens, impacting the efficacy and outcomes for cancer patients. Existing solutions predominantly focus on invasive CNS-targeted gene therapies. This unmet need demands a robust, less-invasive therapeutic option that can serve multiple indications with minimal side effects.

The Technology: MANF protein-based biologic for neuroprotection and inflammation modulation

Harnessing the capabilities of the mesencephalic astrocyte derived neurotrophic factor (MANF) protein, this technology modulates macrophage behavior to promote anti-inflammatory actions, providing neuroprotection against various neuropathies. In Drosophila models of Chemotherapy Induced Peripheral Neuropathy (CIPN), MANF has shown efficacy in providing neuroprotection and therapy. Similarly, sensory neurons from adult mice have demonstrated resilience against chemotherapeutic agents when treated with MANF.

This technology has been validated in both Drosophila and adult mouse models.

Applications:

• Treatment for peripheral neuropathies including Chemotherapy Induced Peripheral Neuropathy (CIPN), diabetic peripheral neuropathy, and idiopathic peripheral neuropathy
• Research tool for understanding MANF-mediated neuroprotective mechanisms
• Investigation of anti-inflammatory processes
• Identification of pathogenic intermediates in the inflammatory cascade

Advantages:

• Non-invasive biologic solution that negates the need for CNS-targeted therapies
• Treatment for several types of peripheral neuropathies
• Can be administered before, during, or after chemotherapy treatments
• Harnesses natural proteins for therapeutic effects, reducing potential side effects
• Demonstrated efficacy in multiple model systems
• Potential for wide patient applicability without specific genetic targeting

Lead Inventor:

Wesley B. Grueber, Ph.D.

Patent Information:

Patent Pending (WO/2024/030951)

Related Publications:

Tech Ventures Reference:

• IR CU20071, CU23006

• Licensing Contact: Kristin Neuman